Key facts
- This page summarizes Avista Capital Partners III GP, L.P.'s Form 4 filing for RVL Pharmaceuticals plc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2023, 16:27.
Avista Capital Partners III GP, L.P. - 27 Jan 2023 Form 4 Insider Report for RVL Pharmaceuticals plc
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 27 Jan 2023
- Net transaction value
- $0
- Reporting owner signature
- Avista Capital Partners III GP, L.P. By: /s/ Ben Silbert, Chief Administrative Officer and General Counsel
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Avista Capital Partners III GP, L.P. filed Form 4 for RVL Pharmaceuticals plc on 30 Jan 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RVLP
transaction
Ordinary Shares
Other
- Transaction value
- $0
- Shares
- -1,032,995
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 27 Jan 2023
- Ownership
- By Avista Capital investment fund
- Footnotes
- F1, F2
RVLP
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 23,730,864
- Date
- 27 Jan 2023
- Ownership
- By Avista Capital investment fund
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares distributed in kind by Orbit Co-Invest III LLC ("Orbit III") to its members, on a pro rata basis, for no consideration.
Footnote F2
Represents shares of the Issuer that were held by Orbit III. Avista Capital Partners III GP, L.P. ("ACP GP") is the manager of Orbit III. As a result, ACP GP may be deemed to have shared voting and investment power with respect to the shares held by Orbit III. Each of Orbit III and ACP GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
Footnote F3
Represents shares of the Issuer held by Avista Healthcare Partners, L.P. ("AHP"). Avista Healthcare Partners GP, Ltd. ("AHP GP") is the general partner of AHP. As a result, AHP GP may be deemed to share voting and investment power with respect to the shares held by AHP. Each of AHP and AHP GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.